Abvc biopharma provides abv-1601 update on phase i site initiation visit conducted at cedars-sinai medical center (csmc)

Fremont, ca, april 10, 2023 (globe newswire) -- via newmediawire -- abvc biopharma, inc. (nasdaq: abvc), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, cns, and ophthalmology, today announced that the phase 1 site initiation visit (siv) of abv-1601 was successfully conducted at cedars-sinai medical center (csmc) in west hollywood, california on march 31, 2023. the siv was an organized meeting to discuss phase i study protocol with the principal investigator, scott a. irwin, m.d., ph.d. and begin training clinical personnel.
ABVC Ratings Summary
ABVC Quant Ranking